View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Research Department
  • Research Department

IBERIAN DAILY 18 DECEMBER (ANÁLISIS BANCO SABADELL)

NEWS SUMMARY: AEDAS HOMES, AENA, AMADEUS, CIE AUTOMOTIVE, EBRO FOODS, NATURGY, NEINOR HOMES, TELEFÓNICA. Awaiting new drivers Most European indices, with the exception of peripheral markets, ended with slight corrections in a session without macroeconomic data. In the STOXX 600, almost all sectors (16/20) ended with gains, led by Basic Resources and Telecommunications vs. the bigger drops of Technology and Construction. On the macro side, in the euro zone, November’s final inflation was cut one...

Research Department
  • Research Department

INFORME DIARIO 18 DICIEMBRE (ANÁLISIS BANCO SABADELL)

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: AEDAS HOMES, AENA, AMADEUS, CIE AUTOMOTIVE, EBRO FOODS, NATURGY, NEINOR HOMES, TELEFÓNICA A la espera de nuevos catalizadores Poco movimiento en Europa en una jornada descargada de datos macro que terminó con tímidas pérdidas en la mayoría de los índices salvo para la periferia. En el STOXX 600, casi todos los sectores (16/20) terminaron con ganancias, lideradas por R. Básicos y Telecomunicaciones frente a las mayores caídas de Tecnología y Construc...

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
 PRESS RELEASE

VIRBAC: Feline Hyperthyroidism: Virbac acquires Thyronorm

VIRBAC: Feline Hyperthyroidism: Virbac acquires Thyronorm Acquisition provides Virbac with a leading specialty product, in a growing segment, to improve the quality of life for senior cats.We are delighted to announce the acquisition of an innovative drug from Norbrook to stabilize feline hyperthyroidism. Virbac will ensure the direct distribution of this treatment under the Thyronorm brand in the United Kingdom, Australia, and New Zealand, and under the Felanorm brand in the United States. In Europe, distribution will continue to be managed by Boehringer Ingelheim and Elanco (in Germany) b...

 PRESS RELEASE

VIRBAC: Hyperthyroïdie féline : Virbac acquiert Thyronorm

VIRBAC: Hyperthyroïdie féline : Virbac acquiert Thyronorm Cette acquisition apporte à Virbac un produit de spécialité de premier plan, sur un segment en croissance, pour améliorer la qualité de vie des chats âgés.Nous sommes ravis d'annoncer l'acquisition auprès de Norbrook d’un médicament innovant pour stabiliser l'hyperthyroïdie féline. Virbac assurera la distribution directe de ce traitement sous la marque Thyronorm au Royaume-Uni, en Australie et Nouvelle-Zélande ainsi qu’aux États-Unis sous la marque Felanorm,. En Europe, la distribution restera gérée par Boehringer Ingelheim et Elanco...

Guy Sips ... (+2)
  • Guy Sips
  • Kristof Samoy
Kristof Samoy
  • Kristof Samoy

CMB.Tech Investment in Chinese ammonia supply

CMB.TECH is investing in the Chinese ammonia supply chain and signed an off-take agreement for green ammonia produced by CEEC in the Jilin Province and will own a minority share in privately owned Andefu, one of China's largest ammonia supply chain companies. While CMB.TECH did not disclose any financials on the deal we estimate linked financials are relatively small. CMB.TECH has a sensible but disciplined investment approach towards decarbonisation. Through the offtake agreement and terminal o...

 PRESS RELEASE

CMB.TECH INVESTS IN CHINESE AMMONIA SUPPLY

CMB.TECH INVESTS IN CHINESE AMMONIA SUPPLY Antwerp, Dec. 16, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMBT”, “CMB.TECH” or “the Company”) is pleased to announce the company is investing in the Chinese ammonia supply chain. CMB.TECH has signed an off-take agreement for green ammonia produced by CEEC Hydrogen Energy (“CEEC”) in Jilin Province and will own a minority share in privately owned Jiangsu Andefu Energy Technology Co., Ltd. (“Andefu”) one of China's largest ammonia supply chain companies. Green ammonia produced...

 PRESS RELEASE

OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Oppo...

OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation Completion of Tedopi’s phase 3 in Non-Small Cell Lung Cancer One or two new rare/specialty indications for LusvertikimabSubcutaneous formulation and combination strategies for Lusvertikimab in UCManagement webcast on Wednesday, December 10th at 6pm CET Nantes, France, December 9, 2025 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced its new three-year s...

 PRESS RELEASE

OSE Immunotherapeutics dévoile son plan stratégique 2026 - 2028 axé s...

OSE Immunotherapeutics dévoile son plan stratégique 2026 - 2028 axé sur quatre leviers de création de valeur OSE Immunotherapeutics dévoile son plan stratégique 2026 - 2028 axé sur quatre leviers de création de valeur Finalisation de la phase 3 de Tedopi® dans le cancer du poumon non à petites cellulesUne ou deux nouvelles indications de maladies rares/spécialisées pour LusvertikimabFormulation sous-cutanée et stratégie de combinaison pour Lusvertikimab dans la rectocolite hémorragiqueWebinaire avec le Management : mercredi 10 décembre à 18 heures Nantes, le 9 décembre 2025, 7 heures 30 ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch